TP53 and liver cancer: Although vaccination against HBV has reduced the incidence of liver cancer,53 many unvaccinated individuals are still at risk of developing liver cancer and HBV infection (257 million in 2015), primarily in Asia and sub-Saharan Africa.54 Moreover, individuals with HBV infection who have a specific mutation in TP53 at position 249 (RS) are more prone to developing HCC.